Prostate Cancer

A Feasibility Study of the Therapeutic Response and Durability of Short-term Androgen-targeted Therapy in Early Prostate Cancer Managed with Surveillance: The Therapeutics in Active Prostate Surveillance (TAPS01) Study

Tristan Barret\textsuperscript{a,b,\dagger}, Simon Pace\textsuperscript{a,c,d,e,\dagger}, Kelly Leonard\textsuperscript{f}, Jerome Wulff\textsuperscript{g}, Ionut-Gabriel Funingan\textsuperscript{a,c,d,e}, Vincent Gnanapragasam\textsuperscript{a,f,h,i,*}

\textsuperscript{a} Translational Prostate Cancer Group, CRUK Cambridge Cancer Centre, Cambridge, UK; \textsuperscript{b} Department of Radiology, University of Cambridge, Cambridge, UK; \textsuperscript{c} Department of Oncology, University of Cambridge, Cambridge, UK; \textsuperscript{d} Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, UK; \textsuperscript{e} Department of Oncology, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Trust, Cambridge, UK; \textsuperscript{f} Cambridge Urology Translational Research and Clinical Trials Office, Cambridge Biomedical Campus, Addenbrooke’s Hospital, Cambridge, UK; \textsuperscript{g} Cambridge Clinical Trials Unit-Cancer Theme, Cambridge, UK; \textsuperscript{h} Division of Urology, Department of Surgery, University of Cambridge, Cambridge, UK; \textsuperscript{i} Department of Urology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

\textsuperscript{\dagger}Corresponding author. Cambridge Urology Translational Research and Clinical Trials Office, Cambridge Biomedical Campus, Addenbrooke’s Hospital, Keith Day Road, Cambridge CB2 0SL, UK. E-mail address: vjg29@cam.ac.uk (V. Gnanapragasam).

Article info

Article history:
Accepted January 18, 2022

Associate Editor:
Guillaume Ploussard

Keywords:
Prostate cancer
Active surveillance
MRI
Progression
Tumour volume
Gland volume
Tumour to gland volume ratio
Androgen deprivation therapy
Androgen receptor
Apalutamide
Short term androgen targeted therapy

Abstract

\textbf{Background:} Active surveillance (AS) is a preferred management option for men with prostate cancer with favourable prognosis. However, nearly half of men on AS switch to treatment within 5 years, so therapeutic strategies to prevent or delay disease progression could be considered. The androgen receptor is the pre-eminent oncogenic driver in prostate cancer.

\textbf{Objective:} To explore image-based tumour responses and the patient impact of short-duration androgen-targeted therapy (ATT) to abrogate disease progression during AS.

\textbf{Design, setting, and participants:} Men on AS with Cambridge Prognostic Group 1 & 2 (low and favourable intermediate risk) prostate cancer and lesions visible on magnetic resonance imaging (MRI) were recruited to an open-label, single-centre, phase 2 feasibility study of short-term ATT (the TAPS01 study).

\textbf{Intervention:} Apalutamide 240 mg was administered for 90 days.

\textbf{Outcome measurements and statistical analysis:} MRI-measured tumour volume (TV), gland volume (GV), and the TV/GV ratio were calculated at baseline, at day 90 (end of treatment), and at 6- and 18-month follow-up. Quality of life metrics were measured at day 0, day 90, and 6 weeks after ATT.

\textbf{Results and limitations:} Eleven patients (40% of eligible men approached) agreed to participate, of whom nine completed treatment. At day 90, the median percentage reduction was –38.2\% (range –51.8\% to –23.5\%) for GV, –54.2\% (range –74.1\% to –23.5\%) for TV.
1. Introduction

Active surveillance (AS) is an increasingly accepted strategy for the management of prostate cancer with favourable prognosis [1–3]. More than 20% of men will progress to active treatment while on AS within a median of 2–3 yr [4,5]. Within 5 yr, up to 40% of men will have converted to active treatment, which is a high attrition rate for what should be favourable disease [4,5]. There is understandable concern among both clinicians and patients about not treating disease that may evolve over time. Conversely, the only current alternative is radical or ablative treatment, which carry the risks of side effects and complications [1]. This “all or nothing” approach offers an ideal opportunity to consider alternative therapeutic strategies. One of these is the concept of disease-modifying drugs that may delay or prevent progression so that men might never require active treatment [6].

Modern AS practice has been revolutionised by recent advances including precision baseline diagnostics, image-based follow-up, and better risk-stratified approaches to disease classification [7–11]. High-quality imaging with multiparametric magnetic resonance imaging (mpMRI) in particular offers an unprecedented ability to monitor real-time changes in tumour growth [9,12]. This, coupled with a better understanding of men who are at the highest risk of progression, positions AS as a unique space for testing therapeutics to alter the natural trajectory of early disease [7,11]. Indeed, the US Food and Drug Administration have recently conducted a workshop on relevant endpoints for this new therapeutic space [13].

The concept of abrogating disease progression while on surveillance is an attractive one for both clinicians and patients [14]. The most promising target for therapy remains the androgen signalling pathway, with 5α reductase inhibitors (5ARIs) the option most often tested to date [15]. A recent meta-analysis involving more than 2000 men concluded that 5ARIs could delay disease progression, although many of the studies included were noted to be of low quality [16]. More recently, it has been reported that 5ARI treatment reduces MRI-defined lesion conspicuity and tumour volume in men on AS [17]. However, concerns that long-term androgen therapy may induce tumour adaptation have so far reduced enthusiasm for adopting 5ARI or other androgen-targeted therapy (ATT) in routine practice [18]. By contrast, short-term ATT may have the desired specific antitumour effects without the risk of longer-term tumour adaptation [19–21].

We hypothesised that short-term ATT, particularly with more selective next-generation antiandrogens, may be a potential therapeutic intervention to reduce tumour progression on AS. We further considered that mpMRI-based imaging would be ideal for noninvasive measurement of the response and clinical durability of any effect. To test our hypothesis, we undertook a feasibility study using apalutamide, a next-generation androgen receptor antagonist that does not also act as an agonist [22–24]. Apalutamide binds to the androgen receptor with seven- to tenfold greater affinity in comparison to bicalutamide, and studies have shown good tolerability profiles in men with prostate cancer [22–24]. Its pure antagonistic properties and good tolerability profile make apalutamide a very attractive agent for a short-term intervention strategy to block androgen receptor signalling for men on AS.

Our goal was to assess the feasibility of trial recruitment, drug efficacy, and patient tolerance and hence to evaluate if a formal future trial testing this approach in men on AS would be justified.

2. Patients and methods

2.1. Study cohort

Therapeutics in Active Prostate Surveillance 01 (TAPS01) was a single-centre, single-arm, open-label, phase 2 feasibility trial (NCT03365297, REC 18/EE/0047) to test the selective tumour response to short-term apalutamide treatment. Following written informed consent, men aged...
≥18 yr and on AS with Cambridge Prognostic Group 1 or Cambridge Prognostic Group 2 prostate cancer were invited to participate [7]. The 5 strata Cambridge Prognostic Groups (CPG) have recently been adopted as the new standard for risk-classification of prostate cancer by the UK National Institute for Health and Care Excellence (NICE) replacing the older-3 tier model (https://www.nice.org.uk/guidance/ng131/resources/prostate-cancer-diagnosis-and-management-pdf-6614174312133). CPG 1 and 2 are comparable to low and favourable-intermediate risk disease. Men had to have been on AS for at least 6 months beforehand and a similar time since any prior biopsy event to be considered eligible. Other inclusions were Eastern Cooperative Oncology Group performance status of 0–2 and diagnostic mpMRI demonstrating a visible tumour (Likert score >3) congruent with diagnostic biopsy. Exclusion criteria included any contraindication to apalutamide (or its excipients), any change in study baseline mpMRI in comparison to previous imaging, prior treatment, and contraindication to MRI/contrast agents. No man was on prior SARI therapy. The trial opened to recruitment on June 5, 2018, with the last visit by the last patient on July 25, 2019. The trial was monitored by an independent trials steering committee. Adverse events were reported via mpMRI at 90 days from the start of treatment. The a priori sample size was calculated as follows: for a significance level (one-sided) of 5% and 80% power, using the A'Hern method, eight patients would be required to test the response rate of ≥50% (H0) versus >50% (H1). If three or more patients were to be classified as achieving a reduction, the null hypothesis H0 would be rejected. An interim analysis was performed to examine the size of the treatment effect when 50% of the cohort had been recruited and had completed the study. Secondary endpoints were tolerability and side effects assessed using patient-reported outcomes for urinary and sexual function and overall wellbeing. Standard descriptive summary statistics were used for the data summaries. Follow-up imaging at 6 and 18 mo was compared to baseline for each case. Summary statistics were reported to one decimal place greater than the original data. The software package SAS v9.4 (SAS Institute, Cary, NC, USA) was used to produce all summaries. Comparisons between time points and baseline were performed using two-tailed paired-sample t tests (p < 0.05).

3. Results

3.1. Cohort profile

The study recruited 11 patients in total, representing 40% of the eligible men who were approached regarding study participation. Reasons for not taking part were usually related to satisfaction with AS or personal circumstances. One patient did not proceed because of screening failure and another man stopped therapy after 34 d because of an asymptomatic unexplained decrease in neutrophil count, which resolved quickly after treatment cessation (CTCAE grade 3). No patients dropped out because of drug intolerance or physical side effects. Nine patients were evaluable and completed the treatment, assessments, and follow-up. The patient characteristics and demographics are shown in Table 1. Five patients were classified as Cambridge Prognostic Group 1 and four as Cambridge Prognostic Group 2. Prior AS duration ranged from 6 mo to 84 mo, and eight out of nine men had Likert 4–5 lesions. The median initial GV and TV were 39.2 cm$^3$ (range 30.5–135.7) and 0.85 cm$^3$ (range 0.21–1.83), respectively (Table 1).

3.2. Therapeutic response

At day 90 (end of treatment) the median percentage reduction was −38.2% (range −51.8 to −23.5%; p = 0.0001) for GV and −54.2% (range −74.1 to −13.8%; p < 0.0001) for TV (Table 2). The median change in TV/GV ratio was −27.2% (range −61.5 to −7.5%; p < 0.001; Table 2). At 6 mo after treatment, GV had largely returned to baseline (median change 0%; p = 0.95; Table 2). Both TV (median −31.9%; p = 0.0007) and the TV/GV ratio (median −28.7%; p = 0.0009) remained smaller than at baseline (Table 2 and Fig. 1). At a median of 18 mo after treatment, both TV and the TV/GV ratio continued to be smaller than at baseline by a median of −18% and −23.8%, respectively (p = 0.01; Table 2 and Fig. 1). Figure 2 and Supplementary Figure 1 shows exemplar images for two patients at baseline, day 90, and 6 mo and 18 mo after treatment. Patient-level data...
for each case are listed in Supplementary Table 2 (TV and GV) and Supplementary Table 3 (prostate-specific antigen [PSA] density). Although there were individual variations in response, median PSA density levels, despite showing the expected fall during apalutamide treatment, mostly returned to pretreatment level by 6 mo. In one case the PSA drop was sustained up to 18 mo after treatment (Supplementary Table 3).

3.3. QoL measures

QoL assessments were conducted at baseline, at day 90, and at 6 weeks after treatment. Across EORTC QLQ-C30 domains there were reduced scores for global, physical, role, and social functioning between baseline and day 90, but all started to recover by 6 wk after treatment (Table 3). However, there were no changes in emotional or cognitive functioning (Table 3). The mean EQ-5D-5L score was 0.07 points lower at day 90 and remained so at 6 weeks after treatment compared to baseline. The main side effects reported were fatigue (\(n = 5\) men), rash (\(n = 4\)), and breast pain (\(n = 4\)) during treatment and all resolved or were resolving by 6 weeks after the end of drug dosing. No patient discontinued the drug or did not complete the study because of these symptoms.

4. Discussion

In this feasibility study, we observed a specific cytoreductive effect in response to short-term apalutamide as evalu-
ated via MRI prostate tumour measurements. This effect appeared to be durable over the short term despite rapid recovery of overall GV and PSA values. Patient tolerance and self-reported impact on QoL were within expected limits and had started to recover within 6 wk of completing treatment. These findings strongly support the hypothesis that short-duration ATT is a potential therapeutic intervention that warrants further investigation.

Serial prostate MRI is now an indispensable tool in modern AS practice [9,10,12]. Changes on MRI are already considered an important trigger to review AS management and there is significant interest in using MRI as a sole measure to detect tumour progression to avoid repeat biopsies [8,10,12]. MRI is noninvasive, well tolerated by patients, and a more direct measure of tumour changes than PSA alone [8,10,12]. All these attributes make MRI an attractive tool for assessing patients with low-risk prostate cancer.

Table 3 – EORTC QLQ-C30 functional scores during treatment and at the 6-wk review visit (n = 9 patients for all domains and time points).

| Domain                                      | Day 0            | Day 90           | 6 weeks post-treatment |
|---------------------------------------------|------------------|------------------|------------------------|
| **Global health status/QoL**                |                  |                  |                        |
| Mean (SD)                                   | 89.8 (11.6)      | 79.6 (11.1)      | 81.5 (13.7)            |
| Median (range)                              | 91.7 (66.7–100)  | 83.3 (58.3–100)  | 83.3 (58.3–100)        |
| Interquartile range                         | 83.3–100         | 75–83.3          | 75–83.3                |
| **Physical functioning**                    |                  |                  |                        |
| Mean (SD)                                   | 99.3 (2.2)       | 91.8 (14.8)      | 92.6 (15.4)            |
| Median (range)                              | 100 (93.3–100)   | 100 (60–100)     | 100 (53.3–100)         |
| Interquartile range                         | 100–100          | 93.3–100         | 93.3–100               |
| **Role functioning**                        |                  |                  |                        |
| Mean (SD)                                   | 100 (0)          | 83.3 (23.6)      | 92.6 (22.2)            |
| Median (range)                              | 100 (100–100)    | 100 (33.3–100)   | 100 (33.3–100)         |
| Interquartile range                         | 100–100          | 66.7–100         | 100–100                |
| **Emotional functioning**                   |                  |                  |                        |
| Mean (SD)                                   | 94.4 (8.4)       | 94.5 (11)        | 95.4 (11.1)            |
| Median (range)                              | 100 (83.3–100)   | 100 (66.7–100)   | 100 (66.7–100)         |
| Interquartile range                         | 83.3–100         | 91.7–100         | 100–100                |
| **Cognitive functioning**                   |                  |                  |                        |
| Mean (SD)                                   | 90.7 (8.8)       | 92.6 (12.1)      | 90.7 (12.1)            |
| Median (range)                              | 83.3 (83.3–100)  | 100 (66.7–100)   | 100 (66.7–100)         |
| Interquartile range                         | 83.3–100         | 83.3–100         | 83.3–100               |
| **Social functioning**                      |                  |                  |                        |
| Mean (SD)                                   | 100 (0)          | 87 (23.2)        | 88.9 (22.1)            |
| Median (range)                              | 100 (100–100)    | 100 (33.3–100)   | 100 (33.3–100)         |
| Interquartile range                         | 100–100          | 83.3–100         | 83.3–100               |

**EORTC QLQ-C30** = European Organization for Research and Treatment of Cancer QoL core 30-item questionnaire; **QoL** = quality of life; **SD** = standard deviation.
and valuable surrogate for investigating and monitoring novel therapy effects in clinical trials. Previously, the use of imaging after ATT was considered challenging because of the significant effect on prostate tissue architecture. However, work by ourselves and others has shown that modern functional MRI methods such as DCE and DWI can reliably detect and measure tumour regions of interest before and after ATT [17,25]. In this study we were able to exploit these innovations to provide a direct noninvasive method for monitoring changes in tumour response over time. Interestingly, while reductions in TV and GV were matched by PSA reductions during treatment, PSA recovery afterwards did not follow changes in TV and were the most variable parameter. This probably reflects the fact that PSA in early cancers is mainly a measure of GV rather than TV dynamics, underscoring its limited utility as an AS monitoring tool in isolation.

QoL changes were, not unexpectedly, seen during treatment. Reference standards for the minimally important difference (MID) to interpret group-level changes in this therapeutic context are unknown [26]. QoL tools are also dependent on the cancer stages in which they are tested [27]. However, if the mean and standard deviation for the group at baseline were used as a measure, then the scores at 90 days and 6 wk were well within that range for each of the three tools used here. Some comparisons from previous studies may also provide context. Pickard et al [26] established an MID for UK cancer patients using the EQ-5D scale of between 0.10 and 0.12, which is notably higher than the values in our study. For the EQ VAS they reported an MID of 8–12, while we observed no changes in mean VAS scores. It is known that apalutamide crosses the blood-brain barrier and has been associated with central nervous system effects [28]. In this study, however, we did not find any significant change in emotional or cognitive scores, which may be a further advantage of the short-duration ATT approach, potentially reducing long-term drug exposure that affects cognition.

The notion of using ATT for early prostate cancer is not new. The Early Prostate Cancer study conducted more than 15 yr ago did not show a survival benefit when bicalutamide was given in early disease [29]. However, this was given as long-term therapy and predates the modern AS era, in which the clinically important endpoint is not survival but avoiding active treatment for disease progression [1,2,5]. Interest in this area has now re-emerged with a better understanding of disease prognosis, the acceptance of AS for mainstream management, and better selective ATT drugs [19]. The ENACT study, for example, has treated men on AS with enzalutamide (NCT02799745) or placebo. As reported in a recent abstract presentation, early data show that at 1 yr the use of enzalutamide increased the negative biopsy rate by 46% and delayed PSA progression by 6 mo compared to placebo. This study did not include state-of-the-art imaging-targeted biopsies or MRI surveillance in the protocol [30]. Schweizer et al [21] reported on short-term ATT with apalutamide in 22 men in AS in the USA using systematic biopsy outcomes as the primary endpoint. The concept of direct intraprostatic antiandrogens has also been recently published by the well-respected AS group from Toronto [31]. In that study the primary measure was a reduction in PSA, but MRI, mainly used to look at the effect on gland volumes, did reveal a reduction in Prostate Imaging-Reporting and Data System score in nine out of 16 men.

Our study has clear limitations as a single-centre small cohort trial of treatment feasibility. Our goal was to establish proof of principle for the treatment approach and the method for monitoring. Therefore we can draw no conclusions at this stage on the longer-term benefit from short-term ATT. As we did not include repeat biopsies, we cannot comment on whether the effect on tumour volume observed is matched by histopathological changes. In the study by Schweizer et al [21], 13/22 men (59%) had no cancer on post-treatment biopsy (day 90) and seven out of 22 (37%) had no residual cancer at 1 yr. Importantly from the safety point of view, no man in our study experienced disease progression and patient acceptance and tolerability were high. Although our median follow-up was only 18 months, we are the first to report the potential durability of the cyto-reductive effect of short-term ATT. These preliminary data support progression to a formal, well-powered trial using clinically relevant endpoints in AS and with MRI as an important component in measuring tumour response. Certainly, the ability to optimally characterise and noninvasively monitor tumours at the outset and during AS is potentially unique in oncological trial design, alongside the ability to detect early nonresponders and to rapidly convert patients to radical treatment. This might be particularly attractive for men on AS who are known to be at higher risk of progression [4–7]. To this end we will be starting a multicentre randomised trial to test the clinical efficacy of short-term ATT as a means of reducing progression rates on AS. If proven, there is also the possibility that this approach may be suitable for repeat challenges as intermittent therapy to prolong the durability and limit side effects, a method that has been effective in men who require permanent long-term androgen deprivation therapy [32].

5. Conclusions

In summary, we report the successful completion of an exploratory study looking at short-term ATT in men on
AS, and the first to use modern AS methods including MRI as a monitoring tool. The study confirms the acceptability, tolerability, and safety of short-term ATT for patients. We demonstrated early signals of a potentially clinically meaningful and durable therapeutic effect, which we hypothesise may translate into longer-term benefits. We are now taking this forward in a formal clinical trial to test this hypothesis.

Author contributions: Vincent Gnanapragasam had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Gnanapragasam.

Acquisition of data: Barrett, Pacey, Leonard, Funingana.

Analysis and interpretation of data: Gnanapragasam, Wulff, Pacey, Barrett.

Drafting of the manuscript: Gnanapragasam.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Wulff.

Obtaining funding: Gnanapragasam.

Administrative, technical, or material support: Leonard, Funingana.

Supervision: Gnanapragasam.

Other: None.

Financial disclosures: Vincent Gnanapragasam certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (e.g., employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Vincent Gnanapragasam acknowledges speaker fees from Janssen for educational events. The remaining authors have nothing to disclose.

Funding/Support and role of the sponsor: The study was sponsored by Cambridge University NHS Hospital Trust and funded by an unrestricted education grant from Janssen Pharmaceuticals. The sponsors played no direct role in the study.

Acknowledgments: The authors acknowledge infrastructure support from the UK National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre (BRC-1215-20014) and the Cambridge Clinical Trials Unit (CCTU). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. Tristan Barrett also acknowledges research support from Cancer Research UK (Cambridge Imaging Centre grant number C197/A16465), the Engineering and Physical Sciences Research Council Imaging Centre in Cambridge and Manchester, and the Cambridge Experimental Cancer Medicine Centre. The authors would also like to thank the Cambridge Clinical Trials Unit (Cancer theme) and especially Mr Richard Skells (for mer senior trials co-ordinator) for his outstanding work on the study and helping to deliver it ahead of schedule, and the TAPS01 Trial Management Group for their input into the study: Professor Neil Burnett (chair/oncology), Mr. Kasra Saeb-Parsi (urology), and Mr. Jack Jones (patient/lay representative).

Ethics approval: The study was conducted under REC 18/EE/0047 and REC 20/LO/0264.

Data sharing statement: Data are available on request from the corresponding author.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.euros.2022.01.007.

References

[1] National Institute for Health and Care Excellence. Prostate cancer: diagnosis and management. NICE guideline NG13 London, UK: NICE; 2019. https://www.nice.org.uk/guidance/ng131.

[2] Merriel SWD, Hetherington L, Seggie A, et al. Best practice in active surveillance for men with prostate cancer: a Prostate Cancer UK consensus statement. BJU Int 2019;124:47–54.

[3] Ong WL, Evans SM, Evans M, et al. Trends in conservative management for low-risk prostate cancer in a population-based cohort of Australian men diagnosed between 2009 and 2016. Eur Urol Oncol 2021;4:319–22.

[4] Van Hemelrijck M, Ji X, Helleman J, et al. Reasons for discontinuing active surveillance: assessment of 21 centres in 12 countries in the Movember CAP3 Consor tium. Eur Urol 2019;75:523–31.

[5] Dall’Era MA, Albertsen PC, Bangma C, et al. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol 2012;62:976–83. https://doi.org/10.1016/j.euro.2012.05.072.

[6] Gnanapragasam VJ, Barrett T, Pacey S, Warren A. Does modern active surveillance offer an opportunity for new therapeutic strategies in early prostate cancer? BJU Int 2021;127:628–9.

[7] Gnanapragasam VJ, Barrett T, Thankappannair V, et al. Using prognosis to guide inclusion criteria, define standardised endpoints and stratify follow-up in active surveillance for prostate cancer. BJU Int 2019;124:758–67. https://doi.org/10.1111/bju.14800.

[8] Thurtle D, Barrett T, Thankappan-Nair V, et al. Progression and treatment rates using an active surveillance protocol incorporating image-guided baseline biopsies and multiparametric magnetic resonance imaging monitoring for men with favourable-risk prostate cancer. BJU Int 2018;122:59–65. https://doi.org/10.1111/bju.14166.

[9] Moore CM, Giganti F, Albertsen P, et al. Reporting magnetic resonance imaging in men on active surveillance for prostate cancer: the PRECISE recommendations—a report of a European School of Oncology task force. Eur Urol 2017;71:648–55.

[10] Ullrich T, Arsov C, Quentin M, et al. Multiparametric magnetic resonance imaging can exclude prostate cancer progression in patients on active surveillance: a retrospective cohort study. Eur Radiol 2020;30:6042–51. https://doi.org/10.1007/s00330-020-06997-1.

[11] Raldow AC, Zhang D, Chen MH, Bracciortore MH, Moran BJ, D’Amico AV. Risk group and death from prostate cancer: implications for active surveillance in men with favorable-intermediate-risk prostate cancer. JAMA Oncol 2015;1:334–40.

[12] Barrett T, Slough R, Sushentsev N, et al. Three-year experience of a dedicated prostate mpMRI pre-biopsy programme and effect on time to cancer diagnostic pathways. Clin Radiol 2019;74(894):e1–9.

[13] Weinstock C, Suzman D, Klutetz P, et al. Development of treatments for localized prostate cancer in patients eligible for active surveillance: U.S. Food and Drug Administration Oncology Center of Excellence public workshop. J Urol 2020;203:115–9.

[14] Goldberg H, Klaassen Z, Chandrasekar T, Fleshner N. Preventing clinical progression and need for treatment in patients on active surveillance for prostate cancer. Curr Opin Urol 2018;28:46–54.

[15] Loughlin KR. The clinical applications of five-alpha reductase inhibitors. Can J Urol 2011;28:10584–8.

[16] Deng T, Lin X, Duan X, He Z, Zhao Z, Zeng G. Prostate cancer patients can benefit from 5-alpha-reductase inhibitor treatment: a meta-analysis. Peerj 2020;8:e9282. https://doi.org/10.7717/peerj.9282.

[17] Moore CM, Robertson NL, Jichi F, et al. The effect of dutasteride on magnetic resonance imaging defined prostate cancer: MAPPED—a randomized, placebo controlled, double-blind clinical trial. J Urol 2017;197:1106–13.
[18] Azoulay L, Eberg M, Benayoun S, Pollak M. 5α-Reductase inhibitors and the risk of cancer-related mortality in men with prostate cancer. JAMA Oncol 2015;1:314–20.

[19] Moyad MA, Scholz MC. Short-term enzalutamide treatment for the potential remission of active surveillance or intermediate-risk prostate cancer: a case study, review, and the need for a clinical trial. Res Rep Urol 2014;6:71–7.

[20] Cussenot O, Cornu JN, Drouin SJ, et al. Secondary chemoprevention of localized prostate cancer by short-term androgen deprivation to select indolent tumors suitable for active surveillance: a prospective pilot phase II study. World J Urol 2014;32:545–50.

[21] Schweizer MT, True L, Ellis W, et al. Resetting the active surveillance clock: apalutamide in lower risk prostate cancer. Presented at the 21st annual meeting of the Society of Urologic Oncology, 2020. https://suo-abstracts.secure-platform.com/a/solicitations/4/sessiongallery/30/application/859.

[22] Clegg NJ, Wongvipat J, Joseph JD, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res 2012;72:1494–503.

[23] Rathkopf DE, Morris MJ, Fox JJ, et al. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol 2013;31:3525–30.

[24] Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 2018;378:1408–18.

[25] Barrett T, Gill AB, Kataoka MY, et al. DCE and DW MRI in monitoring response to androgen deprivation therapy in patients with prostate cancer: a feasibility study. Magn Reson Med 2012;67:778–85. https://doi.org/10.1002/mrm.23062.

[26] Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes 2007;5:70. https://doi.org/10.1186/1477-7525-5-70.

[27] Rautalín M, Färkkilä N, Sintonen H, et al. Health-related quality of life in different states of breast cancer – comparing different instruments. Acta Oncol 2018;57:622–8. https://doi.org/10.1080/0284186X.2017.1400683.

[28] Ryan C, Wefel JS, Morgans AK. A review of prostate cancer treatment impact on the CNS and cognitive function. Prostate Cancer Prostat Dis 2020;23:207–19. https://doi.org/10.1038/s41391-019-0195-5.

[29] McLeod DG, Iversen P, See WA, et al. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006;97:247–54.

[30] Shore ND, Renzulli J, Fleshner NE, et al. MP62-17 Enzalutamide in patients with localized prostate cancer undergoing active surveillance: ENACT. J Urol 2021;206(Suppl 3):e1099. https://doi.org/10.1097/JU.0000000000002102.17.

[31] Klotz L, Grudén S, Axén N, et al. Liproca Depot: a new antiandrogen treatment for active surveillance patients. Eur Urol Focus 2022. https://doi.org/10.1016/j.euf.2021.02.003, In press.

[32] Abrahamsson PA. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol 2010;57:49–59. https://doi.org/10.1016/j.eururo.2009.07.049.